The Indiabulls Ventures Buyback date has been Recorded dates will be Coming Soon
Indiabulls Ventures is a renowned real estate in India. They offer limitless subscription-based trading plans with no brokerage or interest charges. With SEBI, the organisation is registered as a Stock Broker, Depository Participant, Research Analyst, and Merchant Banker under Category I. The NSE code for Indiabulls Ventures is IBVENTURES, while the BSE code is 532960. As of March 31, 2018, the Indiabulls group has combined revenues of over Rs. 22,114.9 Cr. and PAT of over Rs. 6,072.2 Cr.
Start your investing journey today. How do you open your own demat account for free?
Record Dates
Coming Soon
Buyback Price
₹150 per equity share
Face Value
₹2 per share
Offer Closes On
Coming Soon
Indiabulls Ventures Buyback Price
The Indiabulls Ventures Buyback price is ₹[150 per equity share ].
IPO Overview
Indiabulls Ventures Limited stands as a prominent player in India’s capital market sector, offering top-notch securities and derivative broking services. The company holds registrations with SEBI as a Stock Broker, a Depository Participant, a Research Analyst, and a Category I Merchant Banker. At a price of $150 per equity share, Indiabulls Ventures purchased 6,66,66,666 equity shares, representing about 12.61% of all outstanding equity shares. The entire size of the buyback offer cannot exceed 1000 crores.
Indiabulls Ventures Share Buyback 2023 Details
Buyback Record Date: | – |
Board Meeting Approval: | 11-Oct-2019 |
Public Announcement: | 11-Oct-2019 |
Buyback Offer: | ₹1000 Crore |
Buyback Offer Size: | 12.61% |
Number of Shares: | 6,66,66,666 |
Share Face Value: | ₹2 |
Buyback Price: | ₹150 |
Buyback Type: | Tender Offer |
Company Profile

Indiabulls Ventures operates nine manufacturing units in Tarapur, Maharashtra, and two manufacturing units in Sarigam, Gujarat. These facilities are predominantly GMP certified. The company has a global presence, exporting its products to more than 100 countries. Indiabulls Ventures has obtained approvals from various esteemed authorities including WHO-GMP, ACCREDITATION from JAPAN, IDL China, ANVISA, TGA Australia, COFEPRIS, and COS. In terms of financial performance, the company achieved a total revenue of ₹2,71,824.75 lakhs, ₹2,49,996.17 lakhs, and ₹2,15,930.50 lakhs in the years 2023, 2022, and 2021 respectively.
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.